17 May 2019 - NICE has recommended Revlimid (lenalidomide), a drug that helps to support the immune system to fight blood cancer.
The treatment will now be available on the NHS for patients with a form of blood cancer as a first- and second-line drug, after a new guideline recommended it in combination with dexamethasone as an option for previously untreated multiple myeloma in adults who are not eligible for a stem cell transplant and cannot take thalidomide.
The new indication will benefit approximately 2,100 patients, as the company has a commercial arrangement (via the patient access scheme) which makes lenalidomide available to the NHS with a discount.